Pharmacological activation of AMPK suppresses inflammatory response evoked by IL-6 signalling in mouse liver and in human hepatocytes

Molecular and Cellular Endocrinology

Volumn 375, Issue 1-2, 2013, Pages 68-78

  Nerstedt, Annika ^a   Cansby, Emmelie ^a   Amrutkar, Manoj ^a   Smith, Ulf ^a   Mahlapuu, Margit ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

AMPK; IL 6; Inflammation; JAK1; Liver

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INTERLEUKIN 6; JANUS KINASE 1; METFORMIN; PLACEBO; PROTEIN TYROSINE PHOSPHATASE SHP 2; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LIVER CELL; LIVER LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION;

ADENYLATE KINASE; AMINOIMIDAZOLE CARBOXAMIDE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ENZYME ACTIVATION; ENZYME ACTIVATORS; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEP G2 CELLS; HEPATOCYTES; HUMANS; INTERLEUKIN-6; LIVER; MALE; METFORMIN; MICE; MICE, INBRED C57BL; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RIBONUCLEOTIDES; SERUM AMYLOID A PROTEIN; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84878933932     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.05.013     Document Type: Article

References (79)

1. Abe K., Hirai M., Mizuno K., Higashi N., Sekimoto T., Miki T., Hirano T., Nakajima K. The YXXQ motif in gp 130 is crucial for STAT3 phosphorylation at Ser727 through an H7-sensitive kinase pathway. Oncogene 2001, 20:3464-3474.
2. Akbar D.H. Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome. Endocrine 2003, 20:215-218.
3. Alonzi T., Maritano D., Gorgoni B., Rizzuto G., Libert C., Poli V. Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene inactivation [correction of activation] in the liver. Mol. Cell. Biol. 2001, 21:1621-1632.
4. Argetsinger L.S., Kouadio J.L., Steen H., Stensballe A., Jensen O.N., Carter-Su C. Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity. Mol. Cell. Biol. 2004, 24:4955-4967.
5. Bai A., Ma A.G., Yong M., Weiss C.R., Ma Y., Guan Q., Bernstein C.N., Peng Z. AMPK agonist downregulates innate and adaptive immune responses in TNBS-induced murine acute and relapsing colitis. Biochem. Pharmacol. 2010, 80:1708-1717.
6. Bess E., Fisslthaler B., Fromel T., Fleming I. Nitric oxide-induced activation of the AMP-activated protein kinase alpha2 subunit attenuates IkappaB kinase activity and inflammatory responses in endothelial cells. PLoS ONE 2011, 6:e20848.
7. Brunmair B., Staniek K., Gras F., Scharf N., Althaym A., Clara R., Roden M., Gnaiger E., Nohl H., Waldhausl W., Furnsinn C. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?. Diabetes 2004, 53:1052-1059.
8. Cacicedo J.M., Yagihashi N., Keaney J.F., Ruderman N.B., Ido Y. AMPK inhibits fatty acid-induced increases in NF-kappaB transactivation in cultured human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 2004, 324:1204-1209.
9. Cai D., Yuan M., Frantz D.F., Melendez P.A., Hansen L., Lee J., Shoelson S.E. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 2005, 11:183-190.
10. Cardellini M., Perego L., D'Adamo M., Marini M.A., Procopio C., Hribal M.L., Andreozzi F., Frontoni S., Giacomelli M., Paganelli M., Pontiroli A.E., Lauro R., Folli F., Sesti G. C-174G polymorphism in the promoter of the interleukin-6 gene is associated with insulin resistance. Diabetes Care 2005, 28:2007-2012.
11. Carling D. AMP-activated protein kinase: balancing the scales. Biochimie 2005, 87:87-91.
12. Choy E.H., Isenberg D.A., Garrood T., Farrow S., Ioannou Y., Bird H., Cheung N., Williams B., Hazleman B., Price R., Yoshizaki K., Nishimoto N., Kishimoto T., Panayi G.S. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. 2002, 46:3143-3150.
13. Chung J., Uchida E., Grammer T.C., Blenis J. STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol. Cell. Biol. 1997, 17:6508-6516.
14. Corton J.M., Gillespie J.G., Hawley S.A., Hardie D.G. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells?. Eur. J. Biochem. 1995, 229:558-565.
15. David M., Chen H.E., Goelz S., Larner A.C., Neel B.G. Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol. Cell. Biol. 1995, 15:7050-7058.
16. Dixit M., Bess E., Fisslthaler B., Hartel F.V., Noll T., Busse R., Fleming I. Shear stress-induced activation of the AMP-activated protein kinase regulates FoxO1a and angiopoietin-2 in endothelial cells. Cardiovasc. Res. 2008, 77:160-168.
17. Febbraio M.A., Pedersen B.K. Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. FASEB J. 2002, 16:1335-1347.
18. Feener E.P., Rosario F., Dunn S.L., Stancheva Z., Myers M.G. Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling. Mol. Cell. Biol. 2004, 24:4968-4978.
19. Feng J., Witthuhn B.A., Matsuda T., Kohlhuber F., Kerr I.M., Ihle J.N. Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol. Cell. Biol. 1997, 17:2497-2501.
20. Franckhauser S., Elias I., Rotter Sopasakis V., Ferre T., Nagaev I., Andersson C.X., Agudo J., Ruberte J., Bosch F., Smith U. Overexpression of Il6 leads to hyperinsulinaemia, liver inflammation and reduced body weight in mice. Diabetologia 2008, 51:1306-1316.
21. Fukada T., Tonks N.K. Identification of YB-1 as a regulator of PTP1B expression: implications for regulation of insulin and cytokine signaling. EMBO J. 2003, 22:479-493.
22. Fukushima A., Loh K., Galic S., Fam B., Shields B., Wiede F., Tremblay M.L., Watt M.J., Andrikopoulos S., Tiganis T. T-cell protein tyrosine phosphatase attenuates STAT3 and insulin signaling in the liver to regulate gluconeogenesis. Diabetes 2010, 59:1906-1914.
23. Fyfe A.I., Rothenberg L.S., DeBeer F.C., Cantor R.M., Rotter J.I., Lusis A.J. Association between serum amyloid A proteins and coronary artery disease: evidence from two distinct arteriosclerotic processes. Circulation 1997, 96:2914-2919.
24. Guschin D., Rogers N., Briscoe J., Witthuhn B., Watling D., Horn F., Pellegrini S., Yasukawa K., Heinrich P., Stark G.R., et al. A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin-6. EMBO J. 1995, 14:1421-1429.
25. Hattori Y., Suzuki K., Hattori S., Kasai K. Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension 2006, 47:1183-1188.
26. Heinrich P.C., Behrmann I., Muller-Newen G., Schaper F., Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. 1998, 334(Pt 2):297-314.
27. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374:1-20.
28. Horike N., Sakoda H., Kushiyama A., Ono H., Fujishiro M., Kamata H., Nishiyama K., Uchijima Y., Kurihara Y., Kurihara H., Asano T. AMP-activated protein kinase activation increases phosphorylation of glycogen synthase kinase 3beta and thereby reduces cAMP-responsive element transcriptional activity and phosphoenolpyruvate carboxykinase C gene expression in the liver. J. Biol. Chem. 2008, 283:33902-33910.
29. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
30. Iglesias M.A., Ye J.M., Frangioudakis G., Saha A.K., Tomas E., Ruderman N.B., Cooney G.J., Kraegen E.W. AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. Diabetes 2002, 51:2886-2894.
31. Jager S., Handschin C., St-Pierre J., Spiegelman B.M. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc. Natl. Acad. Sci. USA 2007, 104:12017-12022.
32. Jain N., Zhang T., Kee W.H., Li W., Cao X. Protein kinase C delta associates with and phosphorylates Stat3 in an interleukin-6-dependent manner. J. Biol. Chem. 1999, 274:24392-24400.
33. Jiao H., Berrada K., Yang W., Tabrizi M., Platanias L.C., Yi T. Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1. Mol. Cell. Biol. 1996, 16:6985-6992.
34. Kern P.A., Ranganathan S., Li C., Wood L., Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 2001, 280:E745-E751.
35. Kim H.J., Higashimori T., Park S.Y., Choi H., Dong J., Kim Y.J., Noh H.L., Cho Y.R., Cline G., Kim Y.B., Kim J.K. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 2004, 53:1060-1067.
36. Kim N.H., Lee M.Y., Park S.J., Choi J.S., Oh M.K., Kim I.S. Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3. Immunology 2007, 122:607-614.
37. Kim T.B., Kim S.Y., Moon K.A., Park C.S., Jang M.K., Yun E.S., Cho Y.S., Moon H.B., Lee K.Y. Five-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside attenuates poly (I:C)-induced airway inflammation in a murine model of asthma. Clin. Exp. Allergy 2007, 37:1709-1719.
38. Kim Y.D., Kim Y.H., Cho Y.M., Kim D.K., Ahn S.W., Lee J.M., Chanda D., Shong M., Lee C.H., Choi H.S. Metformin ameliorates IL-6-induced hepatic insulin resistance via induction of orphan nuclear receptor small heterodimer partner (SHP) in mouse models. Diabetologia 2012, 55:1482-1494.
39. Klover P.J., Zimmers T.A., Koniaris L.G., Mooney R.A. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 2003, 52:2784-2789.
40. Klover P.J., Clementi A.H., Mooney R.A. Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 2005, 146:3417-3427.
41. Kunnumakkara A.B., Nair A.S., Sung B., Pandey M.K., Aggarwal B.B. Boswellic acid blocks signal transducers and activators of transcription 3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase SHP-1. Mol. Cancer Res. 2009, 7:118-128.
42. Lim C.P., Cao X. Serine phosphorylation and negative regulation of Stat3 by JNK. J. Biol. Chem. 1999, 274:31055-31061.
43. Liu K.D., Gaffen S.L., Goldsmith M.A., Greene W.C. Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation. Curr. Biol. 1997, 7:817-826.
44. Long Y.C., Zierath J.R. AMP-activated protein kinase signaling in metabolic regulation. J. Clin. Invest. 2006, 116:1776-1783.
45. Lund I.K., Hansen J.A., Andersen H.S., Moller N.P., Billestrup N. Mechanism of protein tyrosine phosphatase 1B-mediated inhibition of leptin signalling. J. Mol. Endocrinol. 2005, 34:339-351.
46. Mahlapuu M., Johansson C., Lindgren K., Hjalm G., Barnes B.R., Krook A., Zierath J.R., Andersson L., Marklund S. Expression profiling of the gamma-subunit isoforms of AMP-activated protein kinase suggests a major role for gamma3 in white skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 2004, 286:E194-E200.
47. Matthews V.B., Allen T.L., Risis S., Chan M.H., Henstridge D.C., Watson N., Zaffino L.A., Babb J.R., Boon J., Meikle P.J., Jowett J.B., Watt M.J., Jansson J.O., Bruce C.R., Febbraio M.A. Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia 2010, 53:2431-2441.
48. Migone T.S., Rodig S., Cacalano N.A., Berg M., Schreiber R.D., Leonard W.J. Functional cooperation of the interleukin-2 receptor beta chain and Jak1 in phosphatidylinositol 3-kinase recruitment and phosphorylation. Mol. Cell. Biol. 1998, 18:6416-6422.
49. Mohanty P., Aljada A., Ghanim H., Hofmeyer D., Tripathy D., Syed T., Al-Haddad W., Dhindsa S., Dandona P. Evidence for a potent antiinflammatory effect of rosiglitazone. J. Clin. Endocrinol. Metab. 2004, 89:2728-2735.
50. Myerburg M.M., King J.D., Oyster N.M., Fitch A.C., Magill A., Baty C.J., Watkins S.C., Kolls J.K., Pilewski J.M., Hallows K.R. AMPK agonists ameliorate sodium and fluid transport and inflammation in cystic fibrosis airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 2010, 42:676-684.
51. Myers M.P., Andersen J.N., Cheng A., Tremblay M.L., Horvath C.M., Parisien J.P., Salmeen A., Barford D., Tonks N.K. TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. J. Biol. Chem. 2001, 276:47771-47774.
52. Nath N., Giri S., Prasad R., Salem M.L., Singh A.K., Singh I. 5-aminoimidazole-4-carboxamide ribonucleoside: a novel immunomodulator with therapeutic efficacy in experimental autoimmune encephalomyelitis. J. Immunol. 2005, 175:566-574.
53. Nerstedt A., Johansson A., Andersson C.X., Cansby E., Smith U., Mahlapuu M. AMP-activated protein kinase inhibits IL-6-stimulated inflammatory response in human liver cells by suppressing phosphorylation of signal transducer and activator of transcription 3 (STAT3). Diabetologia 2010, 53:2406-2416.
54. Ng J., Cantrell D. STAT3 is a serine kinase target in T lymphocytes. Interleukin 2 and T cell antigen receptor signals converge upon serine 727. J. Biol. Chem. 1997, 272:24542-24549.
55. Novotny-Diermayr V., Lin B., Gu L., Cao X. Modulation of the interleukin-6 receptor subunit glycoprotein 130 complex and its signaling by LMO4 interaction. J. Biol. Chem. 2005, 280:12747-12757.
56. Pandey M.K., Sung B., Ahn K.S., Aggarwal B.B. Butein suppresses constitutive and inducible signal transducer and activator of transcription (STAT) 3 activation and STAT3-regulated gene products through the induction of a protein tyrosine phosphatase SHP-1. Mol. Pharmacol. 2009, 75:525-533.
57. Pellegrini S., Dusanter-Fourt I. The structure, regulation and function of the Janus kinases (JAKs) and the signal transducers and activators of transcription (STATs). Eur. J. Biochem. 1997, 248:615-633.
58. Pickup J.C., Mattock M.B., Chusney G.D., Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997, 40:1286-1292.
59. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334.
60. Ramadoss P., Unger-Smith N.E., Lam F.S., Hollenberg A.N. STAT3 targets the regulatory regions of gluconeogenic genes in vivo. Mol. Endocrinol. 2009, 23:827-837.
61. Robertson S.A., Koleva R.I., Argetsinger L.S., Carter-Su C., Marto J.A., Feener E.P., Myers M.G. Regulation of Jak2 function by phosphorylation of Tyr317 and Tyr637 during cytokine signaling. Mol. Cell. Biol. 2009, 29:3367-3378.
62. Sadagurski M., Norquay L., Farhang J., D'Aquino K., Copps K., White M.F. Human IL6 enhances leptin action in mice. Diabetologia 2010, 53:525-535.
63. Sag D., Carling D., Stout R.D., Suttles J. Adenosine 5'-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J. Immunol. 2008, 181:8633-8641.
64. Schuringa J.J., Schepers H., Vellenga E., Kruijer W. Ser727-dependent transcriptional activation by association of p300 with STAT3 upon IL-6 stimulation. FEBS Lett. 2001, 495:71-76.
65. Senn J.J., Klover P.J., Nowak I.A., Zimmers T.A., Koniaris L.G., Furlanetto R.W., Mooney R.A. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J. Biol. Chem. 2003, 278:13740-13746.
66. Serrano-Marco L., Barroso E., El Kochairi I., Palomer X., Michalik L., Wahli W., Vazquez-Carrera M. The peroxisome proliferator-activated receptor (PPAR) beta/delta agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells. Diabetologia 2012, 55:743-751.
67. Simoncic P.D., Lee-Loy A., Barber D.L., Tremblay M.L., McGlade C.J. The T cell protein tyrosine phosphatase is a negative regulator of janus family kinases 1 and 3. Curr. Biol. 2002, 12:446-453.
68. Ueki K., Kondo T., Tseng Y.H., Kahn C.R. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci USA 2004, 101:10422-10427.
69. Uhlar C.M., Whitehead A.S. Serum amyloid A, the major vertebrate acute-phase reactant. Eur. J. Biochem. 1999, 265:501-523.
70. Uysal K.T., Wiesbrock S.M., Marino M.W., Hotamisligil G.S. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997, 389:610-614.
71. Vieira E., Nilsson E.C., Nerstedt A., Ormestad M., Long Y.C., Garcia-Roves P.M., Zierath J.R., Mahlapuu M. Relationship between AMPK and the transcriptional balance of clock-related genes in skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 2008, 295:E1032-E1037.
72. Wang Y., Kinzie E., Berger F.G., Lim S.K., Baumann H. Haptoglobin, an inflammation-inducible plasma protein. Redox Rep. 2001, 6:379-385.
73. Wen Z., Zhong Z., Darnell J.E. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995, 82:241-250.
74. Wormald S., Zhang J.G., Krebs D.L., Mielke L.A., Silver J., Alexander W.S., Speed T.P., Nicola N.A., Hilton D.J. The comparative roles of suppressor of cytokine signaling-1 and -3 in the inhibition and desensitization of cytokine signaling. J. Biol. Chem. 2006, 281:11135-11143.
75. Yamamoto T., Sekine Y., Kashima K., Kubota A., Sato N., Aoki N., Matsuda T. The nuclear isoform of protein-tyrosine phosphatase TC-PTP regulates interleukin-6-mediated signaling pathway through STAT3 dephosphorylation. Biochem. Biophys. Res. Commun. 2002, 297:811-817.
76. Yang Z., Kahn B.B., Shi H., Xue B.Z. Macrophage alpha1 AMP-activated protein kinase (alpha1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. J. Biol. Chem. 2010, 285:19051-19059.
77. Yu C.L., Burakoff S.J. Involvement of proteasomes in regulating Jak-STAT pathways upon interleukin-2 stimulation. J. Biol. Chem. 1997, 272:14017-14020.
78. Zhang Y., Qiu J., Wang X., Zhang Y., Xia M. AMP-activated protein kinase suppresses endothelial cell inflammation through phosphorylation of transcriptional coactivator p300. Arterioscler. Thromb. Vasc. Biol. 2011, 31:2897-2908.
79. Zhao X., Zmijewski J.W., Lorne E., Liu G., Park Y.J., Tsuruta Y., Abraham E. Activation of AMPK attenuates neutrophil proinflammatory activity and decreases the severity of acute lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008, 295:L497-L504.